Form 4: iRhythm EVP Sells Shares Under Pre-Arranged 10b5-1 Plan

iRhythm Technologies' EVP, Chief Risk Officer, Sumi Shrishrimal, sold 653 shares of common stock for $167.12 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Sumi Shrishrimal, Executive Vice President and Chief Risk Officer of iRhythm Technologies, Inc. (IRTC), reported a sale of common stock.
• The transaction involved the disposition of 653 shares of iRhythm Technologies common stock.
• The shares were sold at a price of $167.12 per share.
• The sale occurred on August 22, 2025, with a deemed execution date also on August 22, 2025.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan, which was established by the reporting person on May 23, 2025.
• Following this transaction, Sumi Shrishrimal directly beneficially owns 34,032 shares of iRhythm Technologies common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale could be perceived negatively, the fact that it was executed under a pre-arranged 10b5-1 plan mitigates concerns about its implications for the company's immediate prospects. It is a routine personal financial planning event.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide broader industry context or competitive analysis. Such transactions are common among executives for personal financial planning.

Stakeholder Impact

• Shareholders may note the insider sale, but the pre-arranged nature of the 10b5-1 plan suggests it is for personal financial management rather than a signal of management's view on the company's immediate future.

Key Dates

Recommendation

The reported insider sale by the EVP, Chief Risk Officer, was conducted under a Rule 10b5-1 trading plan established months prior. This indicates a pre-scheduled personal financial transaction rather than a reactive decision based on new material information. As such, this single transaction is unlikely to be a significant indicator of the company's future performance or warrant a change in investment recommendation. Investors should 'hold' and monitor broader company fundamentals and market conditions.

Keywords

iRhythm Technologies, IRTC, Sumi Shrishrimal, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Executive Compensation